September 8, 2023

Antibe Announces Results of 2023 Annual Meeting

TORONTO, CANADA — (September 8, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. … Continued

more
August 14, 2023

Antibe Reports Q1 2024 Interim Financial and Operating Results

– Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study – PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024 –  Ended quarter with $34.3 million in cash and equivalents TORONTO, CANADA — (August 14, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen … Continued

more
June 29, 2023

Antibe Reports Fiscal 2023 Year-End Results and Business Highlights

– Completed transition to otenaproxesul’s new formulation; tablet manufacturing underway – PK/PD study results expected in calendar Q4 2023 with Phase II initiation in Q1 2024 –  Ended year with $38.9 million in cash and equivalents  TORONTO, CANADA — (June 29, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its … Continued

more
April 25, 2023

Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit

TORONTO, CANADA — (April 25, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the Precision in Clinical Trials Summit being held in Boston on May 1 – 2, 2023. Dr. Joseph Stauffer, Antibe’s … Continued

more
April 18, 2023

Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, CANADA — (April 18, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference being held in person on April 25-26, 2023. Scott Curtis, Antibe’s … Continued

more
April 11, 2023

Antibe Provides April 2023 Corporate Update

TORONTO, CANADA — (April 11, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK/PD Study for Otenaproxesul’s New Formulation Further to Antibe’s update of February 15, 2023, the … Continued

more
February 15, 2023

Antibe Reports Q3 2023 Interim Financial and Operating Results

– Recent animal data on otenaproxesul’s new formulation confirm rapid drug uptake and potential for effective pain management – Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months – Ended quarter with $42.4 million in cash and equivalents, providing over two years of runway TORONTO, CANADA — (February 15, … Continued

more

archives

Attention

This is an external link. Click “OK” to continue.

CANCEL OK